针对NLRP3炎症酶来治疗炎症性疾病
Julia Elise Cabral1, Anna Wu1, Haitian Zhou1
1Laboratory of Macromolecular Structure, Department of Molecular Biology and Biochemistry, Charlie Dunlop School of Biological Sciences, University of California, Irvine, Steinhaus Hall, Irvine, CA 92694-3900, USA.
Trends in pharmacological sciences
|May 15, 2025
概括
针对NLRP3炎症体的新型小分子显示出治疗COVID-19和阿尔茨海默氏症等炎症性疾病的前景. 研究重点是优化像MCC950这样的抑制剂,以获得更好的疗效和更少的副作用.
科学领域:
- 免疫学 免疫学 免疫学
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
背景情况:
- NLRP3炎症酶是COVID-19,阿尔茨海默氏症和痛风等疾病中炎症的关键驱动因素.
- 目前针对下游IL-1β的治疗方法不足,并且没有FDA批准的直接NLRP3抑制剂.
- 作为直接NLRP3抑制剂的MCC950显示出潜在的效果,但其效果偏离目标.
研究的目的:
- 审查NLRP3炎症酶在炎症性疾病中的作用.
- 讨论NLRP3抑制剂的临床试验状态.
- 突出针对NLRP3.3的新兴小分子疗法.
主要方法:
- 利用对NLRP3 NACHT领域的结构和药物化学洞察力,以优化支架.
- 研究氧化DNA (oxDNA) 作为一个关键的炎症酶触发器.
- 探索针对NLRP3抑制的皮林域的分子.
主要成果:
- 优化MCC950支架的目标是提高溶解性和临床疗效.
- 针对皮林域显示出抑制NLRP3激活的希望.
- 新兴的小分子为NLRP3介导的炎症提供了新的治疗途径.
结论:
- NLRP3炎症酶是许多炎症状况的关键目标.
- 目前正在进行的研究重点是开发更安全,更有效的NLRP3抑制剂.
- 针对NLRP3的小分子疗法具有显著的临床应用潜力.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
103
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
103
NF-κB-dependent Signaling Pathway
7.2K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.2K
Inflammatory Bowel Disease IV: Pharmacological Management
82
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
82
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
109
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
109


